Hypertension (n = 257) | No hypertension (n = 621) | |||
---|---|---|---|---|
Restrictive (n = 122) | Non-restrictive (n = 135) | Restrictive (n = 303) | Non-restrictive (n = 318) | |
Age (years) | 74 (52;87) | 75 (55;90) | 74 (52;90) | 76 (53;90) |
Male gender | 60% | 55% | 61% | 61% |
BMI (kg/m2) * | 27.2 (18.0;35.3) | 26.5 (19.5;36.0) | 25.3 (18.4;35.3) | 25.0 (18.4;36.7) |
Decelleration time (ms) * | 117 (87;138) | 187 (145;278) | 116 (84;137) | 171 (143;296) |
E/A ratio * | 1.8 (0.6;3.4) | 1.0 (0.6;2.6) | 1.5 (0.6;3.1) | 1.0 (0.6;3.1) |
Creatinine clearance (mL/min/1.73 m2) | 58 (18;97) | 57 (21;99) | 63 (29;100) | 57 (26;96) |
Wall motion index * | 1.3 (0.5;2.0) | 1.6 (0.6;2.0) | 1.1 (0.5;2.0) | 1.4 (0.6;2.0) |
LVEF ≤45% * | 64% | 48% | 75% | 58% |
Left ventricle posterior wall thickness (mm) * | 12 (9;17) | 11 (8;15) | 11 (7;15) | 10 (7;14) |
Smokers | 33% | 28% | 33% | 24% |
Diabetes mellitus * | 19% | 22% | 13% | 12% |
Hyperlipidaemia | 37% | 30% | 30% | 30% |
History of ischemic heart disease | 44% | 45% | 44% | 44% |
Previous stroke or TIA | 15% | 17% | 11% | 10% |
Atrial fibrillation | 44% | 35% | 38% | 38% |
COPD | 19% | 29% | 20% | 24% |
Medications at discharge: | ||||
Betablockers * | 51% | 59% | 43% | 47% |
ACE inhibitors | 55% | 59% | 65% | 56% |
Angiotensin II blockers * | 12% | 10% | 5% | 6% |
Calcium channel blockers * | 15% | 25% | 11% | 12% |
Diuretics | 92% | 96% | 93% | 92% |
Statins | 20% | 21% | 17% | 20% |
Nitrates * | 11% | 25% | 16% | 20% |
Glycosides (digoxin)* | 42% | 27% | 42% | 37% |
Oral anticoagulants | 28% | 24% | 36% | 31% |